NSE: SOLARA | BSE: 541540

Slowing Down Stock

Download real time

441.25 -6.70 (-1.50%)

New 52W Low today

89,286 NSE+BSE Volume

NSE 13 Mar, 2026 3:31 PM (IST)

1,963.1

Market Cap

Above industry Median

Beta 1Year

Very Low volatility

Solara Active Pharma Sciences Ltd. share price target and research reports

Name: Latest research reports of Solara Active Pharma Sciences Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Solara Active Pharma Sciences Ltd.
Rating: 5
Author: ICICI Securities Limited

Latest analyst research reports with target prices and PDF download for SOLARA, BSE:541540 Solara Active Pharma Sciences Ltd.

Search Inside the pdf :

Solara Active Pharma Sciences Ltd.

27 Jan 2023

441.25

-1.50%

On the path to gradual recovery

Buy: Solara Active Pharma Scien...

Target

ICICI Securities Limited

Solara Active Pharma’s (Solara) Q3FY23 performance was above our estimates across all parameters. Revenue was up 16.7% QoQ to Rs.3.9bn (I-Sec: Rs.3.8bn)) with strong recovery in regulated markets.

Solara Active Pharma Sciences Ltd. is trading below all available SMAs

Solara Active Pharma Sciences Ltd.

10 Nov 2022

441.25

-1.50%

Gradual recovery; valuations comfortable

Buy: Solara Active Pharma Scien...

Target

ICICI Securities Limited

Solara Active Pharma’s (Solara) Q2FY23 performance was below our estimates across all parameters.

Promoters unpledged 9.28% of shares in last quarter. Total pledge stands at 26.04% of promoter holdings

Solara Active Pharma Sciences Ltd.

05 Aug 2022

441.25

-1.50%

Slow recovery in base; Valuations comfortable

Buy: Solara Active Pharma Scien...

ICICI Securities Limited

Solara Active Pharma’s (Solara) Q1FY23 performance was below our estimates across all parameters. Revenue declined 18.6% YoY (-8.5%QoQ) to Rs.3.3bn (I-Sec: Rs.3.8bn) with slower recovery across segments.

Solara Active Pharma Sciences Ltd. is trading below all available SMAs

Solara Active Pharma Sciences Ltd.

02 May 2022

441.25

-1.50%

Result Update:Solara Active

Not Rated: Solara Active Pharma Scien...

Axis Direct

The company's business seems to have lost momentum due to lower demand for Ibuprofen as well a lack of pricing power in the non-regulated market, and higher input and logistic costs. The company's margins are also at risk, forcing us to keep this scrip Under Review for now.

Promoters unpledged 9.28% of shares in last quarter. Total pledge stands at 26.04% of promoter holdings

Solara Active Pharma Sciences Ltd.

12 Nov 2021

441.25

-1.50%

Result Update:Solara Active

Hold: Solara Active Pharma Scien...

Target

Axis Direct

We expect the whole API industry to continue facing challenges due to a fall in realization as well as an increase in cost pressure. We foresee the situation to continue for the next 2-3 quarters and therefore recommend a HOLD rating on the stock with the target price of Rs 1,300/share.

Promoters unpledged 9.28% of shares in last quarter. Total pledge stands at 26.04% of promoter holdings

Solara Active Pharma Sciences Ltd.

05 Aug 2021

441.25

-1.50%

Result Update:Solara Active

Hold: Solara Active Pharma Scien...

Axis Direct

We expect Gross Margins to be impacted due to an increase in revenue share from non-regulated markets and an increase in raw material prices going onwards. Hence, we recommend a HOLD rating on the stock with a target price of INR 1,670 (PE 20x for FY23EPS).

Solara Active Pharma has lost -25.28% in the last 3 Months

Solara Active Pharma Sciences Ltd.

04 Aug 2021

441.25

-1.50%

Comprehensive approach in API/CRAMS to drive growth

Buy: Solara Active Pharma Scien...

Motilal Oswal

Comprehensive approach in API/CRAMS to drive growth Motilal Oswal values your support in the Asiamoney Brokers Poll 2021 for India Research, Sales, Corporate Access and...

Solara Active Pharma has lost -34.88% in the last 6 Months

Solara Active Pharma Sciences Ltd.

07 May 2021

441.25

-1.50%

Result Update:Solara Active

Hold: Solara Active Pharma Scien...

Recommendation

Axis Direct

We expect gross margins to be impacted due to an increase in revenue share from the non-regulated market going onwards, therefore recommend HOLD' with a target price of Rs 1,670/share (PE 20x for FY23EPS).

Promoters unpledged 9.28% of shares in last quarter. Total pledge stands at 26.04% of promoter holdings

Solara Active Pharma Sciences Ltd.

24 Feb 2021

441.25

-1.50%

Company Update:Solara Active

Buy: Solara Active Pharma Scien...

Axis Direct

Solara has built a strong and enduring platform that consists of two essential pieces, the outside in and the inside out. In outside in, Solara global presence long-standing customer relationships, breadth of product portfolio.